Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Are Investors Betting Big on LSE:IMM Ahead of Major Clinical Updates?

Why Is LSE:IMM - ImmuPharma Stock Surging 9.9% in March 2026?

Ankur Sharma | 23 March 2026

Is Oncoinvest ASA a Hidden Gem in the Oncology Boom?

What Is Driving LSE:ORU5 - Oncoinvest ASA Stock Surge Today in March 2026?

Ankur Sharma | 23 March 2026

Why Are UK Biotech Stocks Like LSE:AGY Surging in March 2026?

Why Is LSE:AGY - Allergy Therapeutics Stock Rising 3.9% Today in March 2026?

Ankur Sharma | 23 March 2026

Is This the Right Time to Buy Oxford BioDynamics Stock After 11% Drop?

Why Is LSE:OBD - Oxford BioDynamics Stock Falling Today in March 2026?

Ankur Sharma | 20 March 2026

Is LSE:SBTX the biggest biotech buying opportunity after the crash?

Why is LSE:SBTX - SkinBioTherapeutics Plc stock down 35% today in March 2026?

Ankur Sharma | 20 March 2026

Can LSE:PXS - Provexis sustain its breakout rally in 2026?

Why is Provexis stock suddenly trending and going viral among UK small-cap investors in March 2026?

Ankur Sharma | 20 March 2026

What Triggered the Rally in LSE:SPI Shares in March 2026?

Key Reasons Behind the SurgeThe primary driver behind the rally isrenewed takeover speculation and strategic interest. Spire has been in ongoing discussions with private equity firms such as Bridgepoint and Triton, with deadlines for potential bids extended into March 2026.Such developments typically support share …

Team Kalkine | 20 March 2026

Smith & Nephew Slips ~5.3% – Is This a Healthcare Buying Opportunity?

Smith & Nephew PLC, theFTSE 100-listed global medical technology group focused on orthopaedic reconstruction, sports medicine and advanced wound management, saw its shares decline ~5.32 percent on 2 March 2026 to 1,298.50 pence. The drop occurred despite the company reporting solid results for 2025, …

Team Kalkine | 02 March 2026

ConvaTec (LSE:CTEC) Shares Leap 12% on FY25 Beats, Buy Ratings Pile In

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.

Team Kalkine | 24 February 2026

Cizzle Biotechnology (LSE:CIZ) Shares Surge 23% on US Commercial Breakthrough

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research

Team Kalkine | 23 February 2026

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions